Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IMATINIB - Health Canada Drug Approval Details

Approvals/Health Canada/IMATINIB

Authorized

STANDARD

IMATINIB

sivem pharmaceuticals ulc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: c5f070b30d3b43f0
Company: sivem pharmaceuticals ulc
Type: Standard

Approval Details

Approval Id: c5f070b30d3b43f0
Drug Approval Canada Name: IMATINIB
Product Name: IMATINIB
Status: Marketed
Status Date: 2024-04-29
Original Market Date: 2024-04-29
Din: 02521202
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 10:00.00
Atc Original: L01EA01 IMATINIB
Atc Name: l 01 ea 01
Aig Number: 0145503002
Company Name: sivem pharmaceuticals ulc
Company Address: 4705 Dobrin Street, Saint-Laurent, Quebec, Canada, H4R 2P7

Active Ingredients

IMATINIB (IMATINIB MESYLATE)

100 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

c5f070b30d3b43f0

Type

Standard

Back to Health Canada Approvals